198 related articles for article (PubMed ID: 23147734)
1. A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity.
Brauer F; Schmidt K; Zahn RC; Richter C; Radeke HH; Schmitz JE; von Laer D; Egerer L
Antimicrob Agents Chemother; 2013 Feb; 57(2):679-88. PubMed ID: 23147734
[TBL] [Abstract][Full Text] [Related]
2. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
3. Definition of human immunodeficiency virus type 1 gp120 and gp41 cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I alleles in simian-human immunodeficiency virus-infected rhesus monkeys.
Voss G; Letvin NL
J Virol; 1996 Oct; 70(10):7335-40. PubMed ID: 8794394
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
[TBL] [Abstract][Full Text] [Related]
5. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
6. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
7. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ; Lambert DM; Tompkins WA
J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
[TBL] [Abstract][Full Text] [Related]
8. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
9. Polyethylene Glycol 40-Modified Peptide with High Therapeutic Efficacy in Simian-Human Immunodeficiency Virus-Acutely Infected Rhesus Monkeys.
Li M; Cheng S; Ding Y; Wang C; Feng Y; Wang W; Ma L; Li X
J Virol; 2020 Jul; 94(14):. PubMed ID: 32404523
[TBL] [Abstract][Full Text] [Related]
10. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
11. Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.
Zahn RC; Hermann FG; Kim EY; Rett MD; Wolinsky SM; Johnson RP; Villinger F; von Laer D; Schmitz JE
Gene Ther; 2008 Sep; 15(17):1210-22. PubMed ID: 18449216
[TBL] [Abstract][Full Text] [Related]
12. Engineering T-Cell Resistance to HIV-1 Infection via Knock-In of Peptides from the Heptad Repeat 2 Domain of gp41.
Maslennikova A; Kruglova N; Kalinichenko S; Komkov D; Shepelev M; Golubev D; Siniavin A; Vzorov A; Filatov A; Mazurov D
mBio; 2022 Feb; 13(1):e0358921. PubMed ID: 35073736
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides.
Egelhofer M; Brandenburg G; Martinius H; Schult-Dietrich P; Melikyan G; Kunert R; Baum C; Choi I; Alexandrov A; von Laer D
J Virol; 2004 Jan; 78(2):568-75. PubMed ID: 14694088
[TBL] [Abstract][Full Text] [Related]
15. Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail.
Nehete PN; Nehete BP; Hill L; Manuri PR; Baladandayuthapani V; Feng L; Simmons J; Sastry KJ
Virology; 2008 Jan; 370(1):130-41. PubMed ID: 17920095
[TBL] [Abstract][Full Text] [Related]
16. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy.
Chen Y; Jin H; Tang X; Li L; Geng X; Zhu Y; Chong H; He Y
Emerg Microbes Infect; 2022 Dec; 11(1):30-49. PubMed ID: 34821542
[TBL] [Abstract][Full Text] [Related]
17. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
18. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
Jiang X; Jia Q; Lu L; Yu F; Zheng J; Shi W; Cai L; Jiang S; Liu K
Amino Acids; 2016 Dec; 48(12):2867-2873. PubMed ID: 27631437
[TBL] [Abstract][Full Text] [Related]
19. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
20. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]